BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208:134-147. [PMID: 19228515 DOI: 10.1016/j.jamcollsurg.2008.09.007] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Rahnemai-Azar AA, Abbasi A, Acher AW, Weber SM, Pawlik TM. Emerging pathways for precision medicine in management of cholangiocarcinoma. Surg Oncol 2020;35:47-55. [PMID: 32827952 DOI: 10.1016/j.suronc.2020.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kang CM, Suh KS, Yi NJ, Hong TH, Park SJ, Ahn KS, Hayashi H, Choi SB, Jeong CY, Takahara T, Shiozaki S, Roh YH, Yu HC, Fukumoto T, Matsuyama R, Naoki U, Hashida K, Seo HI, Okabayashi T, Kitajima T, Satoi S, Nagano H, Kim H, Taira K, Kubo S, Choi DW. Should Lymph Nodes Be Retrieved in Patients with Intrahepatic Cholangiocarcinoma? A Collaborative Korea-Japan Study. Cancers (Basel) 2021;13:445. [PMID: 33503932 DOI: 10.3390/cancers13030445] [Reference Citation Analysis]
3 Han IW, Jang JY, Kang MJ, Kwon W, Park JW, Chang YR, Kim SW. Role of resection for Bismuth type IV hilar cholangiocarcinoma and analysis of determining factors for curative resection. Ann Surg Treat Res 2014;87:87-93. [PMID: 25114888 DOI: 10.4174/astr.2014.87.2.87] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Ba Y, Yue P, Leung JW, Wang H, Lin Y, Bai B, Zhu X, Zhang L, Zhu K, Wang W, Meng W, Zhou W, Liu Y, Li X. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma. Endosc Int Open 2020;8:E203-10. [PMID: 32010755 DOI: 10.1055/a-0990-9114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jin Z, Kobayashi S, Gotoh K, Takahashi T, Eguchi H, Naka T, Mori M, Doki Y. The Prognostic Impact of Leucine-Rich α-2-Glycoprotein-1 in Cholangiocarcinoma and Its Association With the IL-6/TGF-β1 Axis. J Surg Res 2020;252:147-55. [PMID: 32278969 DOI: 10.1016/j.jss.2020.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang X, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study. Transl Oncol 2021;14:100908. [PMID: 33059123 DOI: 10.1016/j.tranon.2020.100908] [Reference Citation Analysis]
7 Roeksomtawin S, Navasumrit P, Waraprasit S, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Savaraj N, Ruchirawat M. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines. Oncol Lett 2018;16:1529-38. [PMID: 30008833 DOI: 10.3892/ol.2018.8807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hu J, Chen FY, Zhou KQ, Zhou C, Cao Y, Sun HC, Fan J, Zhou J, Wang Z. Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. Oncotarget 2017;8:113817-27. [PMID: 29371948 DOI: 10.18632/oncotarget.22852] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
9 Bagante F, Gani F, Spolverato G, Xu L, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Marsh JW, Pawlik TM. Intrahepatic Cholangiocarcinoma: Prognosis of Patients Who Did Not Undergo Lymphadenectomy. Journal of the American College of Surgeons 2015;221:1031-1040.e4. [DOI: 10.1016/j.jamcollsurg.2015.09.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
10 Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26:125-137. [PMID: 28577718 DOI: 10.1016/j.suronc.2016.12.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
11 Ohira M, Yoshizumi T, Yugawa K, Kosai-Fujimoto Y, Inokuchi S, Motomura T, Mano Y, Toshima T, Itoh S, Harada N, Ikegami T, Soejima Y, Taketomi A, Mori M. Association of inflammatory biomarkers with long-term outcomes after curative surgery for mass-forming intrahepatic cholangiocarcinoma. Surg Today 2020;50:379-88. [PMID: 31667580 DOI: 10.1007/s00595-019-01905-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
12 Rahnemai-Azar AA, Pawlik TM. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. Expert Opin Investig Drugs 2021;30:419-27. [PMID: 33645382 DOI: 10.1080/13543784.2021.1897103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yoh T, Hatano E, Seo S, Terajima H, Uchida Y, Taura K, Yasuchika K, Uemoto S. Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2018;25:299-307. [DOI: 10.1002/jhbp.552] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Xu W, Yu S, Xiong J, Long J, Zheng Y, Sang X. CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma. Aging (Albany NY) 2020;12:1047-86. [PMID: 31956102 DOI: 10.18632/aging.102634] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
15 Waisberg DR, Pinheiro RS, Nacif LS, Rocha-Santos V, Martino RB, Arantes RM, Ducatti L, Lai Q, Andraus W, D'Albuquerque LC. Resection for intrahepatic cholangiocellular cancer: new advances. Transl Gastroenterol Hepatol 2018;3:60. [PMID: 30363713 DOI: 10.21037/tgh.2018.08.03] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
16 Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol. 2010;41:1310-1319. [PMID: 20471664 DOI: 10.1016/j.humpath.2009.10.029] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
17 Raoof M, Dumitra S, Ituarte PHG, Melstrom L, Warner SG, Fong Y, Singh G. Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma. JAMA Surg 2017;152:e170117. [PMID: 28297009 DOI: 10.1001/jamasurg.2017.0117] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
18 Ahn KS, Kang KJ, Kang YN, Kim YH, Kim TS. Confinement to the intrapancreatic bile duct is independently associated with a better prognosis in extrahepatic cholangiocarcinoma. BMC Gastroenterol 2016;16:21. [PMID: 26911927 DOI: 10.1186/s12876-016-0444-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhao HP, Zhang ZH, Zheng AH. Assessment of treatment outcomes in patients with advanced hilar cholangiocarcinoma (stages III-IV): Clinical significance of interventional therapy. Medicine (Baltimore). 2018;97:e11550. [PMID: 30278479 DOI: 10.1097/md.0000000000011550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Huang L, Frampton G, Liang LJ, DeMorrow S. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol 2010; 1(2): 23-29 [PMID: 21607139 DOI: 10.4291/wjgp.v1.i2.23] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
21 McNally ME, Collins A, Wojcik SE, Liu J, Henry JC, Jiang J, Schmittgen T, Bloomston M. Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma. HPB (Oxford). 2013;15:260-264. [PMID: 23458262 DOI: 10.1111/j.1477-2574.2012.00523.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
22 Teng F, Xian YT, Lin J, Li Y, Wu AL. Comparison of Unilateral With Bilateral Metal Stenting for Malignant Hilar Biliary Obstruction. Surg Laparosc Endosc Percutan Tech. 2019;29:43-48. [PMID: 30418421 DOI: 10.1097/sle.0000000000000594] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
23 Joo I, Lee JM. Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection. Abdom Imaging. 2013;38:1334-1350. [PMID: 23925840 DOI: 10.1007/s00261-013-0027-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
24 Zhang H, Shen F, Han J, Shen YN, Xie GQ, Wu MC, Yang T. Epidemiology and surgical management of intrahepatic cholangiocarcinoma. Hepat Oncol 2016;3:83-91. [PMID: 30191028 DOI: 10.2217/hep.15.34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Sapisochín G, Fernández de Sevilla E, Echeverri J, Charco R. Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol 2015; 7(22): 2396-2403 [PMID: 26464755 DOI: 10.4254/wjh.v7.i22.2396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
26 Lafaro KJ, Cosgrove D, Geschwind JF, Kamel I, Herman JM, Pawlik TM. Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract 2015;2015:860861. [PMID: 26089873 DOI: 10.1155/2015/860861] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
27 Zhao W, Yang S, Chen J, Zhao J, Dong J. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway. Life Sci 2018;210:224-34. [PMID: 30193944 DOI: 10.1016/j.lfs.2018.09.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
28 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Boonjaraspinyo S, Boonmars T, Aromdee C, Puapairoj A, Wu Z. Indirect effect of a turmeric diet: enhanced bile duct proliferation in Syrian hamsters with a combination of partial obstruction by Opisthorchis viverrini infection and inflammation by N-nitrosodimethylamine administration. Parasitol Res 2011;108:7-14. [DOI: 10.1007/s00436-010-2031-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
30 Spolverato G, Kim Y, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Clark Gamblin T, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Tran TB, Wallis Marsh J, Pawlik TM. Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Ann Surg Oncol. 2016;23:235-243. [PMID: 26059651 DOI: 10.1245/s10434-015-4642-9] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 16.0] [Reference Citation Analysis]
31 Kim SH, Han DH, Choi GH, Choi JS, Kim KS. Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Propensity Score-Matched Study. J Gastrointest Surg 2019;23:538-44. [DOI: 10.1007/s11605-018-3899-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
32 Yamada T, Nakanishi Y, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Tanaka K, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi T, Hirano S. Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma: Preoperative s-CA19-9 level in ICC. Journal of Gastroenterology and Hepatology 2018;33:1626-33. [DOI: 10.1111/jgh.14124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
33 Liang YY, Shao S, Kuang S, Chen J, Zhou J, He B, Zhang L, Zhang Y, Fowler KJ, Wang J. Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection. Can J Gastroenterol Hepatol 2021;2021:6639600. [PMID: 33748033 DOI: 10.1155/2021/6639600] [Reference Citation Analysis]
34 Liu X, Hakucho A, Liu J, Fujimiya T. Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection. World J Gastroenterol 2014; 20(48): 18249-18259 [PMID: 25561792 DOI: 10.3748/wjg.v20.i48.18249] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Xu L, Yang P, Liang W, Liu W, Wang W, Luo C, Wang J, Peng Z, Xing L, Huang M, Zheng S, Niu T. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. Theranostics 2019;9:5374-85. [PMID: 31410221 DOI: 10.7150/thno.34149] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
36 Lee TH, Kim TH, Moon JH, Lee SH, Choi HJ, Hwangbo Y, Hyun JJ, Choi JH, Jeong S, Kim JH, Park DH, Han JH, Park SH. Bilateral vs unilateral placement of metal stents for inoperable high-grade malignant hilar biliary strictures: a multicenter, prospective, randomized study (with video). Gastrointest Endosc. 2017;86:817-827. [PMID: 28479493 DOI: 10.1016/j.gie.2017.04.037] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 17.3] [Reference Citation Analysis]
37 Allison RR, Zervos E, Sibata CH. Cholangiocarcinoma: An emerging indication for photodynamic therapy. Photodiagnosis and Photodynamic Therapy 2009;6:84-92. [DOI: 10.1016/j.pdpdt.2009.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
38 Hu L, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM. Impact of microvascular invasion on clinical outcomes after curative‐intent resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2018;119:21-9. [DOI: 10.1002/jso.25305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
39 Forner A, Vidili G, Rengo M, Bujanda L, Ponz‐sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019;39:98-107. [DOI: 10.1111/liv.14086] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 26.0] [Reference Citation Analysis]
40 Ma KW, Cheung TT, She WH, Chok KSH, Chan ACY, Dai WC, Tsang SHY, Lo CM. Major postoperative complications compromise oncological outcomes of patients with intrahepatic cholangiocarcinoma after curative resection – A 13-year cohort in a tertiary center. Asian Journal of Surgery 2019;42:164-71. [DOI: 10.1016/j.asjsur.2018.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Skipworth JR, Keane MG, Pereira SP. Update on the management of cholangiocarcinoma. Dig Dis 2014;32:570-8. [PMID: 25034290 DOI: 10.1159/000360507] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
42 Berardi R, Mocchegiani F, Pierantoni C, Federici A, Nicolini D, Morgese F, Onofri A, Risaliti A, Vivarelli M, Cascinu S. Resected biliary tract cancers: a novel clinical-pathological score correlates with global outcome. Dig Liver Dis 2013;45:70-4. [PMID: 22999058 DOI: 10.1016/j.dld.2012.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
43 Li Z, Yuan L, Zhang C, Sun J, Wang Z, Wang Y, Hao X, Gao F, Jiang X. A Novel Prognostic Scoring System of Intrahepatic Cholangiocarcinoma With Machine Learning Basing on Real-World Data. Front Oncol 2020;10:576901. [PMID: 33552957 DOI: 10.3389/fonc.2020.576901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H, Margreiter R, Bale R. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol. 2012;35:1074-1082. [PMID: 22006031 DOI: 10.1007/s00270-011-0288-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
45 Xia XL, Xue D, Xiang TH, Xu HY, Song DK, Cheng PG, Wang JQ. Overexpression of long non-coding RNA CRNDE facilitates epithelial-mesenchymal transition and correlates with poor prognosis in intrahepatic cholangiocarcinoma. Oncol Lett 2018;15:4105-12. [PMID: 29556285 DOI: 10.3892/ol.2018.7815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
46 Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, Zhao X, Li Y, Li Q, Wang H. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5:5696. [PMID: 25526346 DOI: 10.1038/ncomms6696] [Cited by in Crossref: 163] [Cited by in F6Publishing: 223] [Article Influence: 23.3] [Reference Citation Analysis]
47 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Reference Citation Analysis]
48 Du X, Zhang C, Yin C, Wang W, Yan X, Xie D, Zheng X, Zheng Q, Li M, Song Z. High BLM Expression Predicts Poor Clinical Outcome and Contributes to Malignant Progression in Human Cholangiocarcinoma. Front Oncol 2021;11:633899. [PMID: 33828983 DOI: 10.3389/fonc.2021.633899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Roos E, Soer E, Klompmaker S, Meijer L, Besselink M, Giovannetti E, Heger M, Kazemier G, Klümpen H, Takkenberg R, Wilmink H, Würdinger T, Dijk F, van Gulik T, Verheij J, van de Vijver M. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Critical Reviews in Oncology/Hematology 2019;140:8-16. [DOI: 10.1016/j.critrevonc.2019.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
50 Feng D, Xiong Y, Peng Z, Ma Q, Tao T, Liu H, Liang J, Wei Z, Zheng J, Wang L, Zhang H. Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells. Oncol Lett 2017;13:2758-64. [PMID: 28454463 DOI: 10.3892/ol.2017.5789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Yoh T, Seo S, Hatano E, Taura K, Fuji H, Ikeno Y, Okuda Y, Yasuchika K, Kaido T, Okajima H, Uemoto S. A Novel Biomarker-Based Preoperative Prognostic Grading System for Predicting Survival After Surgery for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2017;24:1351-7. [PMID: 28108828 DOI: 10.1245/s10434-016-5708-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
52 Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer. 2019;19:185. [PMID: 30819129 DOI: 10.1186/s12885-019-5391-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 25.0] [Reference Citation Analysis]
53 Lee TH, Moon JH, Park SH. Bilateral metallic stenting in malignant hilar obstruction. Clin Endosc. 2014;47:440-446. [PMID: 25325005 DOI: 10.5946/ce.2014.47.5.440] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
54 Gani F, Nagarajan N, Kim Y, Zhu Q, Luan L, Bhaijjee F, Anders RA, Pawlik TM. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2016;23:2610-2617. [PMID: 27012989 DOI: 10.1245/s10434-016-5101-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 14.8] [Reference Citation Analysis]
55 Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817-837. [PMID: 20637950 DOI: 10.1016/j.suc.2010.04.011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
56 Lu Z, Liu S, Yi Y, Ni X, Wang J, Huang J, Fu Y, Cao Y, Zhou J, Fan J, Qiu S. Serum gamma-glutamyl transferase levels affect the prognosis of patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: A propensity score matching study. International Journal of Surgery 2017;37:24-8. [DOI: 10.1016/j.ijsu.2016.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
57 Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, Shimizu H, Higuchi R, Wakai T, Isayama H, Okusaka T, Tsuyuguchi T, Hirooka Y, Furuse J, Maguchi H, Suzuki K, Yamazaki H, Kijima H, Yanagisawa A, Yoshida M, Yokoyama Y, Mizuno T, Endo I. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci 2021;28:26-54. [PMID: 33259690 DOI: 10.1002/jhbp.870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
58 Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F, Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO). Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010;42:831-838. [PMID: 20702152 DOI: 10.1016/j.dld.2010.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
59 van Vugt JLA, Gaspersz MP, Vugts J, Buettner S, Levolger S, de Bruin RWF, Polak WG, de Jonge J, Willemssen FEJA, Groot Koerkamp B, IJzermans JNM. Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment. Dig Surg. 2019;36:144-152. [PMID: 29455204 DOI: 10.1159/000486867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
60 Yin L, Zhao S, Zhu H, Ji G, Zhang X. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. Sci Rep 2021;11:12166. [PMID: 34108604 DOI: 10.1038/s41598-021-91823-x] [Reference Citation Analysis]
61 Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malagó M. Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther. 2011;34:1063-1078. [PMID: 21933219 DOI: 10.1111/j.1365-2036.2011.04851.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
62 Rassam F, Roos E, van Lienden KP, van Hooft JE, Klümpen HJ, van Tienhoven G, Bennink RJ, Engelbrecht MR, Schoorlemmer A, Beuers UHW, Verheij J, Besselink MG, Busch OR, van Gulik TM. Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience. Langenbecks Arch Surg 2018;403:289-307. [PMID: 29350267 DOI: 10.1007/s00423-018-1649-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
63 Joo I, Lee JM, Yoon JH. Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges. Radiology 2018;288:7-13. [DOI: 10.1148/radiol.2018171187] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 16.3] [Reference Citation Analysis]
64 Solonitsyn E, Dechêne A. Diagnostic Approach to Suspected Perihilar Malignancy. Visc Med 2021;37:3-9. [PMID: 33718479 DOI: 10.1159/000513950] [Reference Citation Analysis]
65 Yoh T, Hatano E, Nishio T, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Significant Improvement in Outcomes of Patients with Intrahepatic Cholangiocarcinoma after Surgery. World J Surg 2016;40:2229-36. [DOI: 10.1007/s00268-016-3583-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
66 Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427-1434. [PMID: 24122810 DOI: 10.1002/hep.26890] [Cited by in Crossref: 237] [Cited by in F6Publishing: 273] [Article Influence: 33.9] [Reference Citation Analysis]
67 Yang SZ, Wang AQ, Du J, Wang JT, Yu WW, Liu Q, Wu YF, Chen SG. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma. World J Gastroenterol 2016; 22(25): 5814-5821 [PMID: 27433094 DOI: 10.3748/wjg.v22.i25.5814] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
68 Ma KW, Chok KSH, She WH, Cheung TT, Chan ACY, Dai WC, Fung JYY, Lo CM. Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis. Hepatol Int 2018;12:167-73. [PMID: 29450868 DOI: 10.1007/s12072-018-9847-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, Dai WC, Lo CM. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019;98:e14013. [PMID: 30702559 DOI: 10.1097/md.0000000000014013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
70 Palen A, Garnier J, Hobeika C, Ewald J, Gregoire E, Delpero JR, Le Treut YP, Turrini O, Hardwigsen J. Oncological relevance of major hepatectomy with inferior vena cava resection for intrahepatic cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)00044-7. [PMID: 33731313 DOI: 10.1016/j.hpb.2021.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Ito K, Ito H, Allen PJ, Gonen M, Klimstra D, D'Angelica MI, Fong Y, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg. 2010;251:675-681. [PMID: 20224368 DOI: 10.1097/sla.0b013e3181d3d2b2] [Cited by in Crossref: 106] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
72 Yoh T, Hatano E, Seo S, Okuda Y, Fuji H, Ikeno Y, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery. World J Surg 2018;42:1848-56. [PMID: 29218465 DOI: 10.1007/s00268-017-4387-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
73 de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, Ferrone CR, Zhu AX, Bauer TW, Walters DM, Gamblin TC, Nguyen KT, Turley R, Popescu I, Hubert C, Meyer S, Schulick RD, Choti MA, Gigot JF, Mentha G, Pawlik TM. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140-3145. [PMID: 21730269 DOI: 10.1200/jco.2011.35.6519] [Cited by in Crossref: 392] [Cited by in F6Publishing: 201] [Article Influence: 39.2] [Reference Citation Analysis]
74 Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015;29:333-43. [PMID: 25966432 DOI: 10.1016/j.bpg.2015.03.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
75 Akhaladze DG, Alikhanov RB, Efanov MG, Kim PP, Kazakov IV, Vankovich AN, Melekhina OV, Kulezneva YV, Tsvirkun VV. [Intrahepatic cholangiocarcinoma followed by vascular invasion: is surgical treatment justified?]. Khirurgiia (Mosk) 2018;:49-57. [PMID: 29953100 DOI: 10.17116/hirurgia2018649-57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Schiffman SC, Reuter NP, McMasters KM, Scoggins CR, Martin RC. Overall survival peri-hilar cholangiocarcinoma: R1 resection with curative intent compared to primary endoscopic therapy. J Surg Oncol. 2012;105:91-96. [PMID: 21815152 DOI: 10.1002/jso.22054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
77 Clark CJ, Wood-Wentz CM, Reid-Lombardo KM, Kendrick ML, Huebner M, Que FG. Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford) 2011;13:612-20. [PMID: 21843261 DOI: 10.1111/j.1477-2574.2011.00340.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
78 Lubezky N, Facciuto M, Harimoto N, Schwartz ME, Florman SS. Surgical treatment of intrahepatic cholangiocarcinoma in the USA. J Hepatobiliary Pancreat Sci. 2015;22:124-130. [PMID: 25187408 DOI: 10.1002/jhbp.157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
79 Shafizadeh N, Grenert JP, Sahai V, Kakar S. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol. 2010;41:485-492. [PMID: 20040392 DOI: 10.1016/j.humpath.2009.10.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
80 Mao K, Liu J, Sun J, Zhang J, Chen J, Pawlik TM, Jacobs LK, Xiao Z, Wang J. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol. 2016;31:417-426. [PMID: 26250532 DOI: 10.1111/jgh.13072] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
81 Krasnodębski M, Grąt M, Jastrzębski M, Szczęśniak M, Morawski M, Zając K, Patkowski W, Zieniewicz K. Unsatisfactory Long-term Results of Liver Transplant in Patients With Intrahepatic Cholangiocarcinoma. Transplant Proc 2020;52:2463-7. [PMID: 32327261 DOI: 10.1016/j.transproceed.2020.02.095] [Reference Citation Analysis]
82 Bi AH, Zeng ZC, Ji Y, Zeng HY, Xu C, Tang ZY, Fan J, Zhou J, Zeng MS, Tan YS. Impact factors for microinvasion in intrahepatic cholangiocarcinoma: a possible system for defining clinical target volume. Int J Radiat Oncol Biol Phys 2010;78:1427-36. [PMID: 20378269 DOI: 10.1016/j.ijrobp.2009.09.069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
83 Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF, Pawlik TM. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217:736-750.e4. [PMID: 23890842 DOI: 10.1016/j.jamcollsurg.2013.05.021] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 10.4] [Reference Citation Analysis]
84 Bale R, Widmann G, Haidu M. Stereotactic Radiofrequency Ablation. Cardiovasc Intervent Radiol 2011;34:852-6. [DOI: 10.1007/s00270-010-9966-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
85 Spolverato G, Kim Y, Alexandrescu S, Popescu I, Marques HP, Aldrighetti L, Clark Gamblin T, Miura J, Maithel SK, Squires MH, Pulitano C, Sandroussi C, Mentha G, Bauer TW, Newhook T, Shen F, Poultsides GA, Wallis Marsh J, Pawlik TM. Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration. Ann Surg Oncol 2015;22:2218-25. [PMID: 25354576 DOI: 10.1245/s10434-014-4223-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
86 Li Y, Tang C, Zhao B, Dong F. Redefining the T1 category of the 8th American Joint Committee on Cancer Staging System for intrahepatic cholangiocarcinoma: A SEER database analysis. Oncol Lett 2020;19:527-32. [PMID: 31897167 DOI: 10.3892/ol.2019.11096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Langella S, Russolillo N, Ossola P, Luzzi AP, Casella M, Lo Tesoriere R, Ferrero A. Recurrence after Curative Resection for Intrahepatic Cholangiocarcinoma: How to Predict the Chance of Repeat Hepatectomy? J Clin Med 2021;10:2820. [PMID: 34206799 DOI: 10.3390/jcm10132820] [Reference Citation Analysis]
88 Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, Khor CJ, Ponnudurai R, Moon JH, Seo DW, Pantongrag-Brown L, Sangchan A, Pisespongsa P, Akaraviputh T, Reddy ND, Maydeo A, Itoi T, Pausawasdi N, Punamiya S, Attasaranya S, Devereaux B, Ramchandani M, Goh KL; Asia-Pacific Working Group on Hepatobiliary Cancers. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2013;28:593-607. [PMID: 23350673 DOI: 10.1111/jgh.12128] [Cited by in Crossref: 135] [Cited by in F6Publishing: 113] [Article Influence: 16.9] [Reference Citation Analysis]
89 Wu Q, Fan H, Lang R, Li X, Zhang X, Lv S, He Q. Overexpression of 14-3-3σ Modulates Cholangiocarcinoma Cell Survival by PI3K/Akt Signaling. Biomed Res Int 2020;2020:3740418. [PMID: 32685476 DOI: 10.1155/2020/3740418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Tsukagoshi M, Wada S, Yokobori T, Altan B, Ishii N, Watanabe A, Kubo N, Saito F, Araki K, Suzuki H, Hosouchi Y, Kuwano H. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Cancer Sci. 2016;107:116-122. [PMID: 26608587 DOI: 10.1111/cas.12853] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
91 Tummanatsakun D, Proungvitaya T, Roytrakul S, Limpaiboon T, Wongkham S, Wongkham C, Silsirivanit A, Somintara O, Sangkhamanon S, Proungvitaya S. Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma. Biomolecules 2019;9:E413. [PMID: 31454981 DOI: 10.3390/biom9090413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
92 Gao Y, Zhou R, Huang JF, Hu B, Cheng JW, Huang XW, Wang PX, Peng HX, Guo W, Zhou J, Fan J, Yang XR. Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Front Oncol 2021;11:704042. [PMID: 34327143 DOI: 10.3389/fonc.2021.704042] [Reference Citation Analysis]
93 Yamashita YI, Shirabe K, Beppu T, Eguchi S, Nanashima A, Ohta M, Ueno S, Kondo K, Kitahara K, Shiraishi M, Takami Y, Noritomi T, Okamoto K, Ogura Y, Baba H, Fujioka H. Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: A multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Gastroenterol Surg 2017;1:136-42. [PMID: 29863136 DOI: 10.1002/ags3.12018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
94 de Meijer VE, Kalish BT, Puder M, Ijzermans JNM. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. British Journal of Surgery 2010;97:1331-9. [DOI: 10.1002/bjs.7194] [Cited by in Crossref: 160] [Cited by in F6Publishing: 142] [Article Influence: 14.5] [Reference Citation Analysis]
95 Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:93541-93550. [PMID: 29212171 DOI: 10.18632/oncotarget.19972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
96 Reitz S, Slam K, Chambers LW. Biliary, pancreatic, and hepatic imaging for the general surgeon. Surg Clin North Am. 2011;91:59-92. [PMID: 21184901 DOI: 10.1016/j.suc.2010.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, Mabrut JY, Adham M, Pruvot FR, Gigot JF. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg. 2013;100:274-283. [PMID: 23124720 DOI: 10.1002/bjs.8950] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 13.9] [Reference Citation Analysis]
98 Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford). 2010;12:134-138. [PMID: 20495658 DOI: 10.1111/j.1477-2574.2009.00149.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
99 Rahnemai-Azar AA, Weisbrod AB, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Rev Gastroenterol Hepatol 2017;11:439-49. [PMID: 28317403 DOI: 10.1080/17474124.2017.1309290] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
100 Kato Y, Takahashi S, Gotohda N, Konishi M. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. J Gastrointest Surg 2016;20:1435-43. [PMID: 27250990 DOI: 10.1007/s11605-016-3180-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
101 Spolverato G, Maqsood H, Vitale A, Alexandrescu S, Marques HP, Aldrighetti L, Gamblin TC, Pulitano C, Bauer TW, Shen F, Poultsides G, Maithel S, Marsh JW, Pawlik TM. Readmission After Liver Resection for Intrahepatic Cholangiocarcinoma: a Multi-Institutional Analysis. J Gastrointest Surg 2015;19:1334-41. [DOI: 10.1007/s11605-015-2826-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
102 Bale R, Schullian P, Haidu M, Widmann G. [Stereotactic Radiofrequency Ablation (SRFA) of intrahepatic cholangiocellular carcinomas: a minimal invasive alternative to liver resection]. Wien Med Wochenschr 2013;163:128-31. [PMID: 23392811 DOI: 10.1007/s10354-013-0182-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
103 Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011;53:1363-1371. [PMID: 21480336 DOI: 10.1002/hep.24227] [Cited by in Crossref: 187] [Cited by in F6Publishing: 209] [Article Influence: 18.7] [Reference Citation Analysis]
104 Rahnemai-Azar AA, Pandey P, Kamel I, Pawlik TM. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepat Oncol 2016;3:223-39. [PMID: 30191045 DOI: 10.2217/hep-2016-0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
105 He C, Zhang Y, Song Y, Wang J, Xing K, Lin X, Li S. Preoperative CEA levels are supplementary to CA19-9 Levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer. 2018;9:3117-3128. [PMID: 30210635 DOI: 10.7150/jca.25339] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
106 Fruscione M, Pickens RC, Baker EH, Martinie JB, Iannitti DA, Hwang JJ, Vrochides D. Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review. Curr Probl Cancer. 2020;100614. [PMID: 32622478 DOI: 10.1016/j.currproblcancer.2020.100614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
107 Mejia JC, Pasko J. Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Clin North Am 2020;100:535-49. [PMID: 32402299 DOI: 10.1016/j.suc.2020.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
108 Conci S, Ruzzenente A, Viganò L, Ercolani G, Fontana A, Bagante F, Bertuzzo F, Dore A, Pinna AD, Torzilli G, Iacono C, Guglielmi A. Patterns of Distribution of Hepatic Nodules (Single, Satellites or Multifocal) in Intrahepatic Cholangiocarcinoma: Prognostic Impact After Surgery. Ann Surg Oncol 2018;25:3719-27. [PMID: 30088126 DOI: 10.1245/s10434-018-6669-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
109 Choi JH, Lee SH, You MS, Shin BS, Choi YH, Kang J, Jang S, Paik WH, Ryu JK, Kim YT. Step-wise endoscopic approach to palliative bilateral biliary drainage for unresectable advanced malignant hilar obstruction. Sci Rep 2019;9:13207. [PMID: 31519930 DOI: 10.1038/s41598-019-48384-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105:131-138. [PMID: 21673683 DOI: 10.1038/bjc.2011.199] [Cited by in Crossref: 73] [Cited by in F6Publishing: 128] [Article Influence: 7.3] [Reference Citation Analysis]
111 Kwon W, Jang J, Chang YR, Jung W, Kang MJ, Kim S. Suggestions for Improving Perihilar Cholangiocarcinoma Staging Based on an Evaluation of the Seventh Edition AJCC System. J Gastrointest Surg 2015;19:666-74. [DOI: 10.1007/s11605-014-2732-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
112 Yoh T, Hatano E, Yamanaka K, Nishio T, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Is Surgical Resection Justified for Advanced Intrahepatic Cholangiocarcinoma? Liver Cancer 2016;5:280-9. [PMID: 27781200 DOI: 10.1159/000449339] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
113 Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, Ota T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata M, Chijiiwa K, Nagino M, Hirano S, Wakai T, Wada K, Isayama H, Okusaka T, Tsuyuguchi T, Fujita N, Furuse J, Yamao K, Murakami K, Yamazaki H, Kijima H, Nakanuma Y, Yoshida M, Takayashiki T, Takada T. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci. 2015;22:249-273. [PMID: 25787274 DOI: 10.1002/jhbp.233] [Cited by in Crossref: 119] [Cited by in F6Publishing: 98] [Article Influence: 19.8] [Reference Citation Analysis]
114 Vitale A, Moustafa M, Spolverato G, Gani F, Cillo U, Pawlik TM. Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2016;113:685-91. [PMID: 26936676 DOI: 10.1002/jso.24213] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
115 Massani M, Stecca T, Pauletti B, Marte G, Ruffolo C, Bonariol L, Bassi N. Intrahepatic Cholangiocarcinoma. In: Abdeldayem H, editor. Topics in the Surgery of the Biliary Tree. InTech; 2018. [DOI: 10.5772/intechopen.75516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Yoon SB, Choi MH, Song M, Lee JH, Lee IS, Lee MA, Hong TH, Jung ES, Choi MG. Impact of preoperative body compositions on survival following resection of biliary tract cancer. J Cachexia Sarcopenia Muscle 2019;10:794-802. [PMID: 31037838 DOI: 10.1002/jcsm.12431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
117 Loehrer AP, House MG, Nakeeb A, Kilbane EM, Pitt HA. Cholangiocarcinoma: are North American surgical outcomes optimal? J Am Coll Surg 2013;216:192-200. [PMID: 23266423 DOI: 10.1016/j.jamcollsurg.2012.11.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
118 Xiong X, Sun D, Chai H, Shan W, Yu Y, Pu L, Cheng F. MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma. Biochemical and Biophysical Research Communications 2015;465:262-9. [DOI: 10.1016/j.bbrc.2015.08.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
119 Kim Y, Moris DP, Zhang X, Bagante F, Spolverato G, Schmidt C, Dilhoff M, Pawlik TM. Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol 2017;116:643-50. [DOI: 10.1002/jso.24720] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
120 Zhang XF, Chakedis J, Bagante F, Beal EW, Lv Y, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study. World J Surg 2018;42:849-57. [PMID: 28879598 DOI: 10.1007/s00268-017-4199-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
121 Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. Oncotarget 2017;8:42159-72. [PMID: 28178675 DOI: 10.18632/oncotarget.15020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
122 Wada Y, Shimada M, Yamamura K, Toshima T, Banwait JK, Morine Y, Ikemoto T, Saito Y, Baba H, Mori M, Goel A. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma. Hepatology 2021. [PMID: 33725402 DOI: 10.1002/hep.31803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Kang JS, Higuchi R, He J, Yamamoto M, Wolfgang CL, Cameron JL, Han Y, Son D, Lee S, Choi YJ, Byun Y, Kim H, Kwon W, Kim SW, Park T, Jang JY. Proposal of the minimal number of retrieved regional lymph nodes for accurate staging of distal bile duct cancer and clinical validation of the three-tier lymph node staging system (AJCC 8th edition). J Hepatobiliary Pancreat Sci 2020;27:75-83. [PMID: 31633308 DOI: 10.1002/jhbp.690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Chryssou E, Guthrie JA, Ward J, Robinson PJ. Hilar cholangiocarcinoma: MR correlation with surgical and histological findings. Clin Radiol. 2010;65:781-788. [PMID: 20797463 DOI: 10.1016/j.crad.2010.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
125 Liu B, Hu Y, Qin L, Peng XB, Huang YX. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma. Dig Liver Dis 2019;51:397-411. [PMID: 30314946 DOI: 10.1016/j.dld.2018.08.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
126 陈勇, 曾艳凌, 林志辉. ERCP术前胆总管结石诊断238例. 世界华人消化杂志 2013; 21(19): 1811-1816 [DOI: 10.11569/wcjd.v21.i19.1811] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
127 Okumura S, Kaido T, Hamaguchi Y, Kobayashi A, Shirai H, Fujimoto Y, Iida T, Yagi S, Taura K, Hatano E, Okajima H, Uemoto S. Impact of Skeletal Muscle Mass, Muscle Quality, and Visceral Adiposity on Outcomes Following Resection of Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2017;24:1037-45. [PMID: 27837297 DOI: 10.1245/s10434-016-5668-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
128 Li J, Wang Q, Lei Z, Wu D, Si A, Wang K, Wan X, Wang Y, Yan Z, Xia Y, Lau WY, Wu M, Shen F. Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification. Oncologist. 2015;20:640-647. [PMID: 25956404 DOI: 10.1634/theoncologist.2014-0470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
129 Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 2018;105:848-56. [PMID: 29193010 DOI: 10.1002/bjs.10676] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 15.3] [Reference Citation Analysis]
130 Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. J Gastrointest Surg 2014;18:2136-48. [DOI: 10.1007/s11605-014-2667-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
131 Jonas S, Krenzien F, Atanasov G, Hau HM, Gawlitza M, Moche M, Wiltberger G, Pratschke J, Schmelzle M. Hilar en bloc resection for hilar cholangiocarcinoma in patients with limited liver capacities-preserving parts of liver segment 4. Eur Surg 2018;50:22-9. [PMID: 30459814 DOI: 10.1007/s10353-017-0507-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
132 Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency Ablation in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-Analysis. Journal of Vascular and Interventional Radiology 2015;26:943-8. [DOI: 10.1016/j.jvir.2015.02.024] [Cited by in Crossref: 55] [Cited by in F6Publishing: 94] [Article Influence: 9.2] [Reference Citation Analysis]
133 Wang Z, Sheng YY, Dong QZ, Qin LX. Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis. World J Gastroenterol 2016; 22(10): 3038-3051 [PMID: 26973400 DOI: 10.3748/wjg.v22.i10.3038] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
134 Zhou Y, Wang X, Xu C, Zhou G, Liu X, Gao S, Xu P. Mass‐forming intrahepatic cholangiocarcinoma: Can diffusion‐weighted imaging predict microvascular invasion? J Magn Reson Imaging 2019;50:315-24. [DOI: 10.1002/jmri.26566] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
135 Ni Q, Shen W, Zhang M, Yang C, Cai W, Wu M, Yang J. Prognostic analysis of radical resection for intrahepatic cholangiocarcinoma: a retrospective cohort study. Oncotarget 2017;8:75627-37. [PMID: 29088897 DOI: 10.18632/oncotarget.18465] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
136 Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Jpn J Clin Oncol. 2014;44:570-578. [PMID: 24755544 DOI: 10.1093/jjco/hyu045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
137 Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Handa T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Shirabe K. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br J Cancer. 2020;122:986-994. [PMID: 32015511 DOI: 10.1038/s41416-020-0744-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]